GNH USA

Europe — EMA

Jakavi

GNH USA supplies Jakavi (Ruxolitinib), a JAK inhibitor for myelofibrosis, polycythemia vera and acute graft‑versus‑host disease. Request a quote for supply.

Ruxolitinib

Request sourcing

1
Pack/s

What is Ruxolitinib?

Ruxolitinib, the active ingredient in Jakavi, is a Janus kinase (JAK) inhibitor presented as an oral tablet for oral use. It treats myelofibrosis, polycythemia vera, and acute graft‑versus‑host disease in appropriate patients.

GNH USA supplies Jakavi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

What is Ruxolitinib used for?

Jakavi (ruxolitinib) is indicated for disorders involving abnormal JAK‑STAT signaling.

Myelofibrosis: reduces spleen size and improves disease‑related symptoms. Polycythemia vera: helps control hematocrit and lowers the need for phlebotomy. Acute graft‑versus‑host disease: mitigates severe inflammatory response after stem cell transplantation.

What are the side effects of Ruxolitinib?

Jakavi may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Anemia - Thrombocytopenia - Diarrhea - Upper respiratory tract infection

Serious or Rare Side Effects: - Severe infections, including opportunistic pathogens - Hepatic toxicity with elevated liver enzymes - Reactivation of latent tuberculosis or other serious infections

What precautions apply to Ruxolitinib?

Before initiating Jakavi, clinicians should consider several safety measures.

Monitor blood counts: regular CBC to detect anemia or thrombocytopenia. Assess liver function: periodic LFTs for hepatic toxicity. Screen for infections: evaluate for active TB or viral hepatitis before starting. Use caution in renal impairment: dose may need adjustment. Avoid use in pregnancy: limited data and potential risk. Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

What does Ruxolitinib interact with?

Jakavi can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase ruxolitinib exposure. - Strong CYP3A4 inducers: may reduce therapeutic effect. - Live vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely): - Anticoagulants: may enhance bleeding risk. - Immunosuppressants: additive infection risk. - Concomitant chemotherapy agents: overlapping myelosuppression.

Frequently asked questions

What conditions is Jakavi used to treat?+
Jakavi is approved for three primary indications: myelofibrosis, where it helps shrink an enlarged spleen and relieves symptoms; polycythemia vera, where it assists in controlling hematocrit levels and reduces the need for regular phlebotomy; and acute graft‑versus‑host disease, where it dampens the severe inflammatory response that can occur after allogeneic stem cell transplantation.
How does ruxolitinib work?+
Ruxolitinib blocks the activity of Janus kinase 1 and 2 (JAK1/JAK2), key enzymes in the JAK‑STAT signaling cascade. By inhibiting these kinases, the drug reduces phosphorylation of STAT proteins, leading to decreased transcription of cytokine‑driven genes that promote abnormal cell growth and inflammation in the targeted diseases.
What determines the dose of Jakavi?+
The appropriate dose of Jakavi is individualized by the prescribing clinician based on the specific indication, patient weight, blood counts, liver and kidney function, and any concomitant medications. Dosage adjustments may be required over time to maintain efficacy while minimizing toxicity.
Is Jakavi safe during pregnancy or breastfeeding?+
Safety data for ruxolitinib in pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be ruled out, Jakavi is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefit justifies the potential risk.
How do I order Jakavi from GNH USA?+
To request Jakavi, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and the necessary import documentation.
How does Jakavi compare with other JAK inhibitors?+
Jakavi (ruxolitinib) is a first‑generation JAK1/JAK2 inhibitor, whereas other agents such as fedratinib target JAK2 more selectively. Clinical choice often depends on the specific disease, prior therapy, side‑effect profile, and patient comorbidities. Jakavi has a well‑established efficacy record in myelofibrosis and polycythemia vera, while newer agents may offer alternative dosing or safety considerations.
What are the recommended storage conditions for Jakavi?+
Jakavi tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep the medication in its original blister pack, protect it from moisture and direct sunlight, and store it out of reach of children.
How is Jakavi administered?+
Jakavi is taken orally as a tablet. Patients should swallow the tablet whole with water; it may be taken with or without food. The exact timing and frequency are determined by the prescriber and should be followed exactly as instructed.
What are the most serious risks associated with Jakavi?+
The most serious adverse events include severe or opportunistic infections, significant cytopenias such as anemia and thrombocytopenia, and hepatic toxicity manifested by elevated liver enzymes. Patients should be monitored closely for signs of infection, bleeding, or liver dysfunction throughout therapy.
Who should not use Jakavi?+
Jakavi is contraindicated in individuals with known hypersensitivity to ruxolitinib or any tablet excipients. It should also be avoided in patients with active severe infections, uncontrolled liver disease, or those who are pregnant. Clinicians must evaluate each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Ruxolitinib
Route
Oral Use
Manufacturer
Novartis Europharm Limited
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU